CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

SHANGHAI, Oct. 5, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced that the United States (US) Food and Drug Administration (FDA) has granted orphan drug designat... Biopharmaceuticals, Oncology, FDA CARsgen Therapeutics, CAR-T, cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news